Patient Data

Name:陳XX
Gender: female
Age: 53y/o
Marital Status: Married

Chief Complaint

Epigastralgia for one month

Present Illness(1)

- She had chronic dry cough for half year
- She went to 亞東 hospital and was admitted for 10 days in March for left pleural effusion.
- The thoracocentesis showed no confirmed diagnosis and no malignancy.

Present Illness(2)

 The dry cough improved afterwards, but she got fever and epigastralgia during this time.

 2 weeks ago, sharp epigastralgia associated anorexia happened. (epigastric area; radiated to back, peri-umbilical, and supra-pubic area)

Present Illness(3)

- Cough with bloody sputum
- Body weight loss for 4 kg
- She visited our GI OPD on April, 11th for second opinion.
- The abdominal sono showed an isoechoic mass at pancreatic body with arterial vessels enhacement.

Present Illness (4)

- The CT revealed heterogenous hypodense mass, arising from pancreatic body and head.
- Multiple metatstatic lymphadenopathy at paravaval and paraaortic region.
- Minimal pleural effusion at left side.

Lab data

April 13th: CEA (血液) [<4.6 ng/ml] 2.49CA199 (血液) [<37 U/ml] 12.13 April 17th: RBC(4.2~6.1*10 e6/uL): 3.27 Hct(37~52%): 31.0 Neutro(40~74%): 78.7 CRP(0.0~0.8 mg/dl):1.5

Image findings

 X-ray:
 1.Faint consolidation
 2.Cardiomegaly with tortuous aortic knob.

3. Blunting of left CP angle(minimal pleural effusion).





Lateral view



• KUB:

- 1.Radiopaque densities over right L4 paraspinal region
- 2.Non-specific bowel gas pattern.
- 3. Fecal retention in colon.























CT guided biopsy(May 5th):





Pathology

 Aspiration cytology:(May 5th)
 Some nests or sheet tumor cells with pleomorphic tumor nuclei and prominent nucleoli.
 Eccentric cytplasm is seen.

Adenocarcinoma is cosidered.

Impression

- Pancreatic head tumor, nature?
- Left pleural effusion, cause?
- Nomocytic anemia,cause
- Myoma uteri s/p ATH

Treatment

Admission routine

Symptom care for GI disturbance

Discussion Pancreatic cancer

Epidemiology

- The forth leading cause of cancer death in US.
- The second most common cause of death from GI malignancy.
- Its incidence is higher in developing countries.

Risk factors

- Age: mean age of seventh and eighth decades.
- Male gender, Jewish religion, and black race.(less than 2 folds)
- Smoking(1.5~5.5 folds)
- Genetic predisposition, medical history, family history
- DM?
- Chronic Pancreatitis

Clinical Presentation

- Early symptoms: nonspecific abdominal discomfort, nausea, vomiting, sleeping difficulties, anorexia, and generalized malaise.
- Late symptoms: Postprandial epigastric pain, *jaundice*(pancreatic head, obstruction), pruritus, claylike stool, and *weight loss*.

Specific Lab. findings

- A patient history, PE and serum bilirubin and alkaline phosphatase can be point to pancreatic cancer, but not diagnostic.
- CA-199: may help confirm diagnosis in symptomatic patients and predict prognosis and recurrence after operation, but lack sensitivity and specificity
- B-HCG and CA72-4

Typical Image







ERCP



EUS



Staging

TNM System

Tis Carcinoma in situ

T1 Tumor limited to the pancreas 2 cm or less in greatest dimension

T2 Tumor limited to the pancreas >2 cm in greatest dimension

T3 Tumor extends directly into any of the following: duodenum, bile duct, peripancreatic tissues

T4 Tumor extends directly into any of the following: stomach, spleen, colon, adjacent large vessels

N0 No regional lymph node metastases

N1 Regional lymph node metastases

- **MO** No distant metastases
- M1 Distant metastases

TABLE 3 Tumor, Node, Metastasis Staging System for Pancreatic Cancer

Stage	Classifications	Clinical classification	Stage distribution at diagnosis (%)	Five-year survival rate (%)
0	Tis, NO, MO	Resectable	7.5	15.2
IA	T1, N0, M0			
IB	T2, N0, M0			
IIA	T3, N0, M0			
IIB	T1-3, N1*, M0	Locally advanced	29.3	6.3
111	T4, any N, MO			
IV	Any T, any N, M1	Metastatic	47.2	1.6

Tis = in situ carcinoma; N0 = no regional lymph node metastasis; M0 = no distant metastasis; T1 = tumor is limited to the pancreas and is 0.8 in (2 cm) or smaller; T2 = tumor is limited to the pancreas and is larger than 0.8 in; T3 = tumor extends beyond the pancreas and does not involve celiac axis or superior mesenteric artery; N1 = regional lymph node metastasis; T4 = tumor involves celiac axis or superior mesenteric artery; N1 = regional lymph nodes; T = primary tumor; M1 = distant metastasis.

*—Tumors with regional lymph node involvement are sometimes considered surgically resectable if nodes are within the resection area.

Information from references 28 and 29.

Treatment

- Resectable lesion: Tumor arising in the tail of the pancreas and those of >4 cm are rarely resectable.
- Surgical resection is the only potentially curative treatment for patients with pancreatic cancer, although many patients are not candidates for resection.

- Only 10~15% can receive Whipple resection at the time of diagnosis.
- Pylorus-preserving pancreaticoduodenostomy: the same longterm survival benefits as the standard Whipple procedure(shorter operative time and reduced blood loss, decreasing the need for blood transfusions.)

- Adjuvant therapy for resectable pancreatic cancer: postoperative 5-FU and radiation
- Locally unresectable lesions:
 - ERCP with stent placement or palliative bypass surgery(biliary obstruction)
 - Celiac plexus block (debilitating pain)

Locally advanced diseases:

Radiation therapy alone can relieve pain and possibly prolong survival.

Combined modality therapy with 5-FU and radiation can prolong survival for 5-10 months.

 Metastatic pancreatic cancer: Palliation of symptoms! Gemcitabine is better than 5-FU because of its ability to improve quality of life.

Prognosis

• Overall 5 year survival rate: 3%

- Patients who have a resection are alive at 5 years: 20%
- Likely increasing long-term cure: Tumor <2 cm, LN w/o metastasis, and no major vessels involvment.

Reference

- Feldman: Sleisenger & Fordtran's Gastrointestinal and Liver Disease, 7th ed.,
- Medicine Recall Second Edition James D.Bergin

Pancreatic cancer.

Brand R - *Dis Mon* - 01-OCT-2004; 50(10): 545-55 From NIH/NLM MEDLINE

Pancreatic Cancer: Diagnosis and Management

 ROBERT FREELOVE, M.D., Smoky Hill Family Medicine Residency Program, Salina, Kansas

American Family Physician Volume 73, Number 3 February 1, 2006